Roivant Sciences expects a $950 million upfront payment from Moderna in July 2026. This payment is part of a $2.25 billion global settlement resolving patent infringement claims. The dispute centered on lipid nanoparticle technology used in Moderna’s COVID-19 vaccine. The agreement involves Roivant’s subsidiary Genevant and Arbutus Biopharma. This settlement eliminates major legal uncertainty for the company.
Roivant detailed upcoming clinical milestones in its fourth-quarter fiscal 2025 report. Topline data from a Phase 2 trial of mosliciguat is expected in the second half of 2026. Mosliciguat targets pulmonary hypertension associated with interstitial lung disease. The company also anticipates late 2026 updates for autoimmune candidate IMVT-1402. These updates include a potentially registrational trial for rheumatoid arthritis.